Latest TroVax Stories
LUGANO, Switzerland and COPENHAGEN, Denmark, February 5, 2015 /PRNewswire/ -- - Elsiglutide is a GLP-2 receptor agonist with potential as a first-ever therapy to help cancer
BOTHELL, Wash. and VANCOUVER, B.C., Sept.16, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc.
AUSTIN, Texas, Sept.
ENSPIRIT Trial to Continue as Planned Following Completion of the First of Two Interim Futility Analyses BOTHELL, Wash. and VANCOUVER, British Columbia, Aug.
Trial Progressing On Track; BETHESDA, Md., Aug.
AUSTIN, Texas, Aug.
ThermoDox® Continues to Demonstrate Impressive Local Response Rate in Refractory Patients LAWRENCEVILLE, N.J., July 24, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies.
LONDON, June 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Retrospective Study of Roswell Park Patients Documents Safety and Benefit of Complex Immunotherapy Buffalo, NY (PRWEB) May 06, 2014 A retrospective study
- A political dynamiter.